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significant improvement in survival. By modeling our 
preclinical study on current clinic workflows, we show clear 
compatibility with modern patient care, thus heightening the 
translational significance. 
 
Material and Methods: AGuIX (Nano-H, Lyon, France) is a 
gadolinium-based nanoparticle that has been proposed for an 
upcoming clinical trial. We performed in vitro cell uptake and 
radiosensitization studies of a pancreatic cancer cell line in 
preclinical (220kVp) and clinical (6 MV and 6 MV FFF) beams. 
MRI was used to monitor tumor uptake and biodistribution. 
Due to their small size (2-3 nm), the GdNP have good renal 
clearance and long blood circulation (around 20-30 min in 
mice). 
In vivo radiation therapy studies were performed to 
characterize the effect of AGuIX as a radiosensitizer 
(n=8/cohort). Histology was performed to measure the 
increase in damage in the tumor and to evaluate the toxicity 
in healthy tissues.  
 
Results: The in vitro results demonstrate a dose 
enhancement factor (DEF) of 1.37 (p<0.005) when the 
combination of irradiation and GdNP is used with the 220kV 
and a DEF of 1.26 for the clinical 6MV FFF. The maximum 
tumor uptake and tumor/muscle ratio is reached 15 minutes 
after IV injection. The in vivo results demonstrated 
statistically significant tumor regression (P<0.001) and 
increase in median survival (p<0.005) for AGuIX combined 
with radiation vs. radiation alone. There was no observed 
increase in toxicity in the surrounding healthy organs. 
 
 
 
Conclusion: MRI contrast and radiosensitization have been 
demonstrated in a preclinical pancreatic tumor model. There 
is a strong translational potential for AGuIX with modern and 
likely future MRI-guided radiation therapy procedures 
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Purpose or Objective: The value of healthcare can be 
defined as the additional health outcomes gained for each 
euro spent. Thus, understanding costs, and their origins, of a 
medical intervention is key to the estimation of value. 
Costing studies to date have yielded highly variable results 
largely due to which and how resources have been analyzed. 
A rigorous health economics approach requires the cost of 
the real resources used to be identified (ISPOR, 2007). We 
report on such an approach to the estimation of the cost of 
radiation therapy. 
 
Material and Methods: A Time-Driven Activity Based Costing 
(TDABC) model was created for external photon beam 
radiotherapy at the national level. The model was developed 
in an iterative manner by a panel of experts, taking into 
account current knowledge of resources, products, and 
clinical processes. The resources were identified through a 
systematic review of the literature from 1981 to 2015. In 
TDABC, resource unit costs per minute are defined as the 
ratio of gross expense to available capacity. The products, 
defined as courses of treatment for specific tumor 
indications, were derived from the decision trees developed 
by the Collaboration for Cancer Outcomes, Research and 
Evaluation (CCORE). The process map was derived from that 
developed by the AAPM (2012, Ford). 
 
Results: Resources are organized in 3 categories: personnel, 
equipment and overhead. Products are grouped per organ 
site and target volume. For each of these, treatment 
complexity and diversity are addressed by extending the 
AAPM process map in three ways:  
1. six technique categories, specified as follows: single-field, 
2D-RT, 3D-CRT, IMRT, rotational IMRT and stereotactic 
techniques;  
2. eight possible fractionation schedules can be defined;  
3. some steps along the patient care pathway are identified 
separately from the 7 high level steps, see figure.  
These, reflecting an additional level of treatment 
complexity, are optional and hence not necessarily applicable 
to all treatment courses. 
The core input required is the time of personnel’s 
involvement at each process step for every technique and 
product. This TDABC approach yields two classes of output:  
1. costs, at the level of the resources, activities and 
products, the latter being the sum of the costs of the 
component process steps; and  
2. resource utilization efficiency. 
 
Fig1. HERO Process map 
 
 
Conclusion: A TDABC model for external photon beam 
radiotherapy is developed for use at the national level. In the 
next step, the model is being tested in close collaboration 
with selected European Radiotherapy Societies, by 
introducing nation-specific data on the resources consumed, 
monetary values and resources’ time devoted to each step, 
reflecting complexity. These data generate national cost 
estimates per course for a range of radiotherapy treatments. 
The cost estimates and details of the methodology will be 
presented. 
 
